Climb Bio (CLYM) Competitors $1.21 -0.03 (-2.42%) As of 05/21/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CLYM vs. OLMA, BNTC, ARCT, DBVT, TRDA, ITOS, HUMA, IMMP, HRTX, and CMPXShould you be buying Climb Bio stock or one of its competitors? The main competitors of Climb Bio include Olema Pharmaceuticals (OLMA), Benitec Biopharma (BNTC), Arcturus Therapeutics (ARCT), DBV Technologies (DBVT), Entrada Therapeutics (TRDA), iTeos Therapeutics (ITOS), Humacyte (HUMA), Immutep (IMMP), Heron Therapeutics (HRTX), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry. Climb Bio vs. Olema Pharmaceuticals Benitec Biopharma Arcturus Therapeutics DBV Technologies Entrada Therapeutics iTeos Therapeutics Humacyte Immutep Heron Therapeutics Compass Therapeutics Olema Pharmaceuticals (NASDAQ:OLMA) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Do institutionals & insiders hold more shares of OLMA or CLYM? 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 19.4% of Olema Pharmaceuticals shares are owned by company insiders. Comparatively, 0.8% of Climb Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is OLMA or CLYM more profitable? Climb Bio's return on equity of -42.21% beat Olema Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Olema PharmaceuticalsN/A -53.56% -47.86% Climb Bio N/A -42.21%-41.39% Which has stronger valuation & earnings, OLMA or CLYM? Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOlema PharmaceuticalsN/AN/A-$96.65M-$2.01-2.49Climb BioN/AN/A-$35.12M-$2.38-0.51 Which has more risk and volatility, OLMA or CLYM? Olema Pharmaceuticals has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500. Does the media favor OLMA or CLYM? In the previous week, Olema Pharmaceuticals had 1 more articles in the media than Climb Bio. MarketBeat recorded 8 mentions for Olema Pharmaceuticals and 7 mentions for Climb Bio. Olema Pharmaceuticals' average media sentiment score of 0.70 beat Climb Bio's score of -0.42 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Climb Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend OLMA or CLYM? Olema Pharmaceuticals presently has a consensus target price of $24.50, indicating a potential upside of 389.02%. Climb Bio has a consensus target price of $10.00, indicating a potential upside of 726.45%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts plainly believe Climb Bio is more favorable than Olema Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Olema Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Climb Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the MarketBeat Community favor OLMA or CLYM? Olema Pharmaceuticals received 37 more outperform votes than Climb Bio when rated by MarketBeat users. However, 100.00% of users gave Climb Bio an outperform vote while only 72.22% of users gave Olema Pharmaceuticals an outperform vote. CompanyUnderperformOutperformOlema PharmaceuticalsOutperform Votes3972.22% Underperform Votes1527.78% Climb BioOutperform Votes2100.00% Underperform VotesNo Votes SummaryOlema Pharmaceuticals and Climb Bio tied by winning 8 of the 16 factors compared between the two stocks. Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLYM vs. The Competition Export to ExcelMetricClimb BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.77M$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-0.578.9226.8419.71Price / SalesN/A253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book0.316.466.794.50Net Income-$35.12M$143.98M$3.23B$248.18M7 Day Performance0.83%2.03%1.53%0.20%1 Month Performance-5.47%4.11%10.06%12.37%1 Year PerformanceN/A-2.87%16.72%7.04% Climb Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLYMClimb Bio2.5394 of 5 stars$1.21-2.4%$10.00+726.4%N/A$81.77MN/A-0.579Positive NewsAnalyst RevisionGap UpOLMAOlema Pharmaceuticals2.2652 of 5 stars$4.69+4.2%$24.50+422.4%-46.5%$320.61MN/A-2.1470BNTCBenitec Biopharma2.4171 of 5 stars$13.50-0.6%$24.71+83.1%+42.3%$316.59M$80,000.00-8.9420News CoverageAnalyst ForecastAnalyst RevisionARCTArcturus Therapeutics2.9267 of 5 stars$11.64+7.4%$57.80+396.6%-59.3%$315.69M$138.39M-5.24180DBVTDBV Technologies2.7867 of 5 stars$11.26-1.9%$15.50+37.7%+48.6%$308.41M$15.73M-2.5080Gap DownTRDAEntrada Therapeutics2.947 of 5 stars$8.12+1.9%$25.67+216.1%-51.0%$308.18M$172.22M5.11110News CoverageAnalyst ForecastAnalyst RevisionITOSiTeos Therapeutics2.9745 of 5 stars$7.97+4.9%$17.86+124.1%-54.4%$305.04M$35M-2.5390Positive NewsAnalyst RevisionGap UpHigh Trading VolumeHUMAHumacyte2.3029 of 5 stars$1.89+1.1%$11.71+519.8%-66.7%$293.18M$1.57M-1.41150Analyst RevisionGap UpIMMPImmutep1.4058 of 5 stars$1.98+8.2%$8.50+329.3%-39.9%$289.16M$5.14M0.002,021Gap DownHigh Trading VolumeHRTXHeron Therapeutics3.8615 of 5 stars$1.87+8.7%$5.50+194.1%-45.3%$285.30M$148.52M-10.39300Positive NewsCMPXCompass Therapeutics3.678 of 5 stars$2.02+1.0%$13.13+549.8%+28.8%$279.33M$850,000.00-5.4620 Related Companies and Tools Related Companies Olema Pharmaceuticals Competitors Benitec Biopharma Competitors Arcturus Therapeutics Competitors DBV Technologies Competitors Entrada Therapeutics Competitors iTeos Therapeutics Competitors Humacyte Competitors Immutep Competitors Heron Therapeutics Competitors Compass Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLYM) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLYM Stock Free CLYM Stock Alerts